CEO Myers Buys $100K in Quoin Private Placement at $4.88
QNRX sits 94% above its 52-week low of $3.25 on light trading volume (0.4× avg).
Summary
CEO Michael Myers bought $99,991 of Quoin ADSs and warrants in the company's $50M private placement at $4.88 per ADS, joining two other insiders in the offering.
Key Events · Ownership and Investor Activity · QNRX
-
CEO Buys $100K in Private Placement
Michael Myers acquired 20,490 ADSs and 10,245 warrants for $99,991.20 at $4.88 per ADS on 2026-08-31, the same terms as all investors in the $50M placement.
-
Insider Participation Reaches ~$180K
Myers' purchase follows Director Culverwell's $29,992 and CFO Lawlor's $49,991 in the same placement, bringing total disclosed insider buying to approximately $180K.
-
Warrant Terms Tie to Clinical Milestone
The 10,245 warrants are exercisable at $6.10 per ADS and expire in five years or 30 days after the Netherton Syndrome trial primary endpoint announcement.
-
Post-Transaction Holdings
Myers now directly holds 37,713 ADSs and 10,245 warrants, a meaningful increase in his personal stake.
Analysis · QNRX · Life Sciences
CEO Michael Myers acquired 20,490 ADSs and 10,245 warrants for $99,991.20 at $4.88 per ADS in the company's $50M private placement, joining Director Culverwell and CFO Lawlor in insider participation. The purchase brings total disclosed insider buying in the placement to approximately $180K, reinforcing management's alignment with shareholders at a time when the company faces going-concern doubt and a widening net loss. The warrants are exercisable at $6.10 per ADS and expire in five years or 30 days after the Netherton Syndrome trial primary endpoint announcement, tying a portion of the CEO's economics to clinical success.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNRX was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $3.25 to $41.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.